id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9830 R35235 |
Vajda (Carbamazepine) (Controls unexposed, sick), 2013 | Palate/lip malformation | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.41 [0.01;20.58] C | 0/361 0/147 | 0 | 361 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8411 R26710 |
Jentink (Carbamazepine), 2010 | Cleft lip (with or without palate) | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: Yes | no data | 1/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5529 R16228 |
Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 | Cleft lip | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.19 [0.09;54.89] C | 1/72 0/52 | 1 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S302 R15854 |
Artama (Carbamazepine), 2005 | Cleft lip/ cleft palate | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 0.23 [0.01;4.86] C | 0/805 2/939 | 2 | 805 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 0.59 [0.09;4.07] | 3 | 1,238 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine; 3: Carbamazepine) (Controls unexposed, sick) ; 4: Carbamazepine;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded